Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > ORGANIZATION
ORGANIZATION
- Priority of Japan Investment Lowered at 27% of Multinational Firms: JPMA Poll
November 2, 2022
- JPMA Applauds Drug Discovery Startup Support in New Economic Package
October 31, 2022
- Japan Needs New Forum for Top-Level Dialogue Including Global CEOs: PhRMA Chair
October 28, 2022
- Over 80% of Wholesaler Reps Say Shipment Adjustments Take Up Most of Their Time: Survey
October 21, 2022
- Look at Drug Prices as Long-Term Investment, Not as Cost: EFPIA President
October 7, 2022
- EFPIA Chief Prods Japan on Mutual Trial Data Recognition, Cooperation to Boost Attractiveness to Rival US, China
October 7, 2022
- EFPIA Japan Appoints Takafumi Horii as New Vice Chair
October 6, 2022
- JMA Chuikyo Rep Urges Savings from Off-Year Drug Price Cuts to Be Allocated to Medical Fees
October 5, 2022
- Generic Use Rate at 79.8% in April-June, Flat YOY: JGA
September 29, 2022
- Policy Veterans’ Group Proposes Simple Drug Price Maintenance Scheme for Patented Meds
September 28, 2022
- 3 Cell & Gene Therapies Make Up More than Half of Top 100 Bills in FY2021: Payer
September 22, 2022
- Sales Reps in Japan Decrease for 8 Years Straight as Voluntary Redundancy Weighs: FY2021 Report
September 21, 2022
- Shionogi’s COVID Pill Might Not Be Applicable for Emergency Approval: JPMA Exec
September 16, 2022
- JPMA Managing Director Tanaka to Retire, Ex-Chugai Official to Take Over
September 16, 2022
- JPMA to Present Proposal on Value-Based Drug Pricing at Upcoming Panel Hearing
September 16, 2022
- FPMAJ Investigating Supply Status for 60% of All Drugs, Tally Due Out by Year-End
September 14, 2022
- FPMAJ-Eyed Overhaul of Price Revision Rules Likely to Curb Price Falls, Cover JP-Listed Meds, Essential Drugs and More
September 9, 2022
- Rapid Removal of NHI-Market Price Gap Will Cause Chaos: Pharmacy Industry Chief
September 9, 2022
- JMA President Confirms Need for Profits from NHI-Market Price Gap
September 8, 2022
- Ex-MHLW Official Isobe, Now at Self-Medication Group, Touts OTC Use to Soften Impact of Off-Year Re-Pricing
September 7, 2022
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…